Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab to prevent progression of colorectal cancer liver metastases after selective portal embolisation
2007-000973-41Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Karolinska University Hospital. Primary endpoints: Change in total sum of liver metastases diameters, Expansion of contralateral liver volume and 1 more. Started Jan 2008; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2007-000973-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000973-41.